Beam Therapeutics (BEAM) Payables (2019 - 2026)

Beam Therapeutics (BEAM) has reported Payables for 8 consecutive years, with $17.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Payables rose 35.56% year-over-year to $17.5 million; the TTM figure through Mar 2026 stood at $17.5 million (up 35.56% YoY), while the FY2025 annual figure was $17.9 million, up 46.13% from the prior year.
• Payables declined to $17.5 million in Q1 2026 per BEAM's latest filing, from $17.9 million in the prior quarter.
• Across five years, Payables topped out at $34.9 million in Q1 2022 and bottomed at $12.1 million in Q3 2023.
• Historically, Payables has averaged $18.7 million across 5 years, with a median of $16.5 million in 2024.
• Annual changes were most pronounced in 2022 — Payables slumped 74.85% — and 2025, when it jumped 46.13%.
• Beam Therapeutics' Payables stood at $27.3 million in 2022, then tumbled by 54.56% to $12.4 million in 2023, then decreased by 1.18% to $12.3 million in 2024, then jumped by 46.13% to $17.9 million in 2025, then retreated by 2.48% to $17.5 million in 2026.
• Business Quant data shows BEAM's Payables at $17.5 million in Q1 2026, $17.9 million in Q4 2025, and $16.0 million in Q3 2025.